At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction with metastatic or inoperable locally advanced disease
- ✓Measurable disease: at least one lesion ≥20 mm by conventional techniques or ≥10 mm by spiral CT
- ✓ECOG performance status 0-2
- ✓Life expectancy ≥12 weeks
- ✕Prior chemotherapy for metastatic or recurrent disease
- ✕Brain metastases
- ✕Allergic reactions to oxaliplatin, irinotecan, or capecitabine or similar compounds
- ✕NYHA class III or IV heart disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
In Brief
A Phase 2 clinical trial evaluating oxaliplatin, irinotecan hydrochloride, and 1 other intervention for Adenocarcinoma of the Gastroesophageal Junction and 8 related conditions. Completed, enrolled 39 participants across 1 site.
Detailed Summary
Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells. This phase II trial is studying how well giving oxaliplatin together with irinotecan and capecitabine works in treating patients with metastatic or inoperable locally advanced gastric cancer or gastroesophageal junction adenocarcinoma (cancer).
Study Details
Timeline
Interventions
Given IV
Given IV
Given orally